The FIGHT-207 trial, led by Jordi Rodon, associate professor of Investigational Cancer Therapeutics at MD Anderson Cancer Center, demonstrated promising early signs of clinical benefit and revealed potential mechanisms of primary and secondary resistance following treatment with the selective FGFR inhibitor pemigatinib in patients with advanced FGFR-altered solid tumors.
Lei Zheng was named executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, and vice president for oncology for the University of Texas Health Science Center at San Antonio.
